表紙
市場調査レポート

米国の糖尿病市場

US Diabetes Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 146121
出版日 ページ情報 英文 85 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
米国の糖尿病市場 US Diabetes Market Outlook 2020
出版日: 2015年08月01日 ページ情報: 英文 85 Pages
概要

糖尿病は米国市場で蔓延しており、2030年までに糖尿病の有病率が14%になると推定されています。さらに、そして糖尿病患者の多くは自らの状況を自覚していません。また、糖尿病関連の医療費は、2014年におよそ2,810億米ドルに達したと見られ、米国政府にとって医療費の大きな負担となっています。

当レポートでは、米国の糖尿病市場について調査分析し、サブマーケット別の市場動向、患者のプロファイル、コストなどの情報を提供し、政府のイニシアチブ、主要企業プロファイルなども含めてお届けいたします。

第1章 アナリストの見解

第2章 調査手法

第3章 市場概要

第4章 患者プロファイル分析

第5章 コストの意味

第6章 市場成長促進因子および課題

  • 市場成長促進因子
    • 糖尿病につながる肥満
    • 可処分所得の増加
    • 寿命の伸び
    • 糖尿病治療に関する意識の高まり
  • 課題
    • 糖尿病治療の従来療法
    • 抗糖尿病薬と糖尿病治療装置の高額費用
    • 長期間に渡る治療薬承認手続き

第7章 糖尿病治療薬市場

  • 経口抗糖尿病薬市場
  • インスリン市場

第8章 インスリンデリバリー装置市場

  • インスリンポンプ
  • インスリンペン
  • インスリンシリンジ
  • インスリンジェット式注射器
  • 経口インスリン
  • 吸入インスリン

第9章 血糖測定器市場

  • グルコース検査紙
  • ランセット
  • 血糖測定器
  • 連続血糖値モニター

第10章 動向および展開

  • 糖尿病の簡易検査用血糖測定器
  • 革新的な薬によって糖尿病を管理
  • 膵島細胞移植−糖尿病患者にとって希望の光

第11章 政府のイニシアチブ

第12章 主要企業

  • 製薬
    • Pfizer
    • GlaxoSmithKline
    • 武田薬品工業
    • Merck
  • インスリンデリバリー装置
    • Novo Nordisk
    • Eli Lilly
    • Sanofi
    • Medtronic
  • 血糖測定器
    • Roche
    • Bayer
    • Abbott Laboratories

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Diabetes has been on the rise for the last few years because of factors such as increased life span of people, hectic lifestyles and increased intake of fatty food. The largest number of cases of diabetes and pre-diabetes are found in the United States, with many still unaware about their diabetes or pre-diabetes condition. It has been estimated that the prevalence of diabetes will be 14% by 2030 in the US. This is likely to put a major burden on healthcare cost of the country. Studies have shown that the total healthcare expenditure in US was US$ 281 Billion in 2014 which was the largest share of the world healthcare expenditure.

The US diabetes care market is segmented into three parts, namely- anti-diabetic drugs segment, insulin delivery devices segment and monitoring and diagnostic devices segment. The most significant growth in the US market has been seen in continuous blood glucose meters, insulin pens, insulin pumps, and anti-diabetic drugs.

The report, “US Diabetes Market Outlook 2020”, highlights the US diabetes market by each segment. The market for each segment has been thoroughly studied and the future market scenario has been forecasted. The prevalence of diabetes and its cost implications have also been indicated in the report. The drivers and challenges of this market have been discussed along with the latest trends and developments. Additionally, information is provided about the key players in this market as well as the steps taken by the government to promote the market. The aforementioned information will help clients in formulating strategies and assessing opportunities in the US diabetes market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Market Overview

4. Patient Profile Analysis

5. Cost Implications

6. Drivers and Challenges

  • 6.1. Drivers for Diabetes Market
    • 6.1.1. Obesity Leading to Diabetes
    • 6.1.2. Rising Disposable Income
    • 6.1.3. Increasing Life Span of People
    • 6.1.4. Increased Awareness about Diabetes Care
  • 6.2. Challenges
    • 6.2.1. Traditional Remedies for Diabetes Care
    • 6.2.2. High Cost of Anti-diabetic Medication and Diagnostic Devices
    • 6.2.3. Long Product Approval Process

7. Diabetes Drugs Market

  • 7.1. Oral Anti-Diabetic Drugs Market
  • 7.2. Insulin Market

8. Insulin Delivery Devices Market

  • 8.1. Insulin Pump
  • 8.2. Insulin Pen
  • 8.3. Insulin Syringes
  • 8.4. Insulin Jet Injectors
  • 8.5. Oral Insulin
  • 8.6. Inhalable Insulin

9. Glucose Monitoring Devices Market

  • 9.1. Glucose Test Strips
  • 9.2. Lancets
  • 9.3. Blood Glucose Meter
  • 9.4. Continuous Blood Glucose Monitors

10. Trends and Developments

  • 10.1. Glucose Meters for Easy Detection of Diabetes
  • 10.2. Novel Drugs Keep Diabetes in Control
  • 10.3. Islet Cell Transplantation- Hope for Diabetes Patients

11. Government Initiatives

12. Competitive Landscape

  • 12.1. Drugs
    • 12.1.1. Pfizer
    • 12.1.2. GlaxoSmithKline
    • 12.1.3. Takeda
    • 12.1.4. Merck
  • 12.2. Insulin Delivery Devices
    • 12.2.1. Novo Nordisk
    • 12.2.2. Eli Lilly
    • 12.2.3. Sanofi
    • 12.2.4. Medtronic Inc.
  • 12.3. Glucose Monitoring Devices
    • 12.3.1. Roche
    • 12.3.2. Bayer
    • 12.3.3. Abbott Laboratories

List of Figures:

  • Figure 3-1: Diabetes Market (Billion US$), 2013 & 2014
  • Figure 4-1: Prevalence of Diabetes (%), 2014 & 2030
  • Figure 4-2: Number of Diabetic Population (Million), 2014 & 2030
  • Figure 5-1: Total Healthcare Expenditure on Diabetes (Billion US$)-US vs. RoW, 2014
  • Figure 5-2: Cost per Person (US$) - US vs. RoW for People with Diabetes, 2014
  • Figure 6-1: Personal Disposable Income (Billion US$), 2008-2014
  • Figure 6-2: Population above 65 Years (Million), 2008-2014
  • Figure 7-1: Oral Diabetic Drugs Market (Billion US$), 2014-2020
  • Figure 7-2: Insulin Market (Billion US$), 2014-2020
  • Figure 7-3: Share of Key Players in Modern Insulin Market (FY 2013)
  • Figure 8-1: Insulin Pumps Market (Billion US$), 2014-2020
  • Figure 8-2: Shares of Key Players in US Insulin Pump Market (2013)
  • Figure 8-3: Insulin Pen Devices Market (Billion US$), 2014-2020
  • Figure 8-4: Insulin Syringes Market (Billion US$), 2014-2020
  • Figure 8-5: Insulin Jet Injectors Market (Billion US$), 2014-2020
  • Figure 9-1: Glucose Test Strips Market (Billion US$), 2014-2020
  • Figure 9-2: Lancets Market (Billion US$), 2014-2020
  • Figure 9-3: Blood Glucose Meter Market (Billion US$), 2014-2020
  • Figure 9-4: Continuous Blood Glucose Monitoring Market (Billion US$), 2014-2020
  • Figure 12-1: Pfizer - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-2: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-3: Takeda - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-4: Merck - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-5: Novo Nordisk - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-6: Eli Lilly - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-7: Sanofi - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-8: Medtronic Inc. - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-9: Roche - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-10: Bayer - Breakup of Revenue by Geographies (%), 2014
  • Figure 12-11: Abbott Laboratories - Breakup of Revenue by Geographies (%), 2014

List of Tables:

  • Table 4-1: Diabetic Patients in Age Group 20-79 Years ('000), 2013 & 2030
  • Table 12-1: Pfizer - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-2: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-3: Takeda - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-4: Merck - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-5: Novo Nordisk - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-6: Eli Lilly - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-7: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-8: Medtronic Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-9: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-10: Bayer - Revenue by Business Segments (Billion US$), 2013 & 2014
  • Table 12-11: Abbott Laboratories - Revenue by Business Segments (Billion US$), 2013 & 2014
Back to Top